Inoue Yuki, Wada Yuko, Sato Makoto, Sato Seiji, Okamoto Takashi, Kanemoto Naohide
Department of Drug Safety Research, Nonclinical Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima, 771-0192 Japan.
PV Operation, Pharmacovigilance Department, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.
Toxicol Res. 2023 May 29;39(4):611-623. doi: 10.1007/s43188-023-00189-x. eCollection 2023 Oct.
FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone) is known to inhibit oxidative phosphorylation as a protonophore, dissipating the proton gradient across the inner mitochondrial membrane. To understand the toxicity of FCCP, 3-day, 2- and 4-week repeated oral dose studies were performed in male rats. In the 3-day and 2-week repeated dose toxicity studies, observations included salivation, increased body temperature, and dead and moribund animals. Increased liver weight was observed in conjunction with hydropic degeneration and centrilobular necrosis of hepatocytes. In addition, pathological changes were observed in the pancreas, testis, epididymal duct, stomach and parotid gland. Electron microscopic examination revealed mitochondrial pleomorphism in the hepatocytes. Swelling of mitochondria was observed in the alpha cells and beta cells of the pancreas. Dilatation of rough endoplasmic reticulum, Golgi bodies and loss of secretory granules were also noted in the beta cells of the pancreas. FCCP was also compared with three other mUncouplers (DNP, OPC-163493 and tolcapone) with regard to in vitro mitochondrial uncoupling (mUncoupling) activities. FCCP produced the peak ΔOCR (oxygen consumption rate) at the lowest concentration (0.4 μM), followed by OPC-163493, tolcapone, and DNP, based on peak values in ascending order of concentration (2.5, 10, and 50 μM, respectively). Considering the relationship between the mUncoupling activity and toxicity profile of the four mUncouplers, there is no parallel relationship between the in vitro mUncoupling activity and the degree of in vivo toxicity. These findings may contribute to the efficient development of new mitochondrial uncoupler candidates.
The online version contains supplementary material available at 10.1007/s43188-023-00189-x.
已知FCCP(羰基氰化物-4-(三氟甲氧基)苯腙)作为质子载体可抑制氧化磷酸化,消除线粒体内膜两侧的质子梯度。为了解FCCP的毒性,对雄性大鼠进行了为期3天、2周和4周的重复口服给药研究。在3天和2周的重复给药毒性研究中,观察到流涎、体温升高以及死亡和濒死动物。观察到肝脏重量增加,同时伴有肝细胞水样变性和小叶中心坏死。此外,在胰腺、睾丸、附睾管、胃和腮腺中观察到病理变化。电子显微镜检查显示肝细胞中线粒体形态异常。在胰腺的α细胞和β细胞中观察到线粒体肿胀。在胰腺的β细胞中还注意到粗面内质网扩张、高尔基体以及分泌颗粒丢失。还就体外线粒体解偶联(m解偶联)活性将FCCP与其他三种解偶联剂(DNP、OPC-163493和托卡朋)进行了比较。基于浓度升序的峰值(分别为2.5、10和50μM),FCCP在最低浓度(0.4μM)时产生峰值ΔOCR(耗氧率),其次是OPC-163493、托卡朋和DNP。考虑到四种解偶联剂的m解偶联活性与毒性特征之间的关系,体外m解偶联活性与体内毒性程度之间不存在平行关系。这些发现可能有助于新的线粒体解偶联剂候选物的高效开发。
在线版本包含可在10.1007/s43188-023-00189-x获取的补充材料。